Milestone PaymentsTBPH remains eligible to receive up to $160M in milestone payments related to Yupelri monotherapy, with $25M looking increasingly achievable due to strong net sales growth.
Regulatory ProgressThe regulatory application submitted by Viatris in China could lead to significant milestone payments and royalties, boosting future revenues.
Sales GrowthYupelri net sales were $58.3M, up 6% year over year, reflecting continued strength in the franchise despite expected seasonality.